Aptar Pharma and COVIRIX Medical collaborate to assess feasibility of adapting Aptar Pharma’s proprietary DPI platform for antiviral delivery.

Researchers conducted an observational study using real‑world data to compare the effectiveness and safety of initiating three fixed‑dose long‑acting muscarinic antagonist (LAMA)-long‑acting beta‑2 ...

Dry Powder Inhalers: A Double Win for COPD and Environment By Dennis Thompson HealthDay ReporterTUESDAY, Feb. 24, 2026 (HealthDay News) — Dry powder inhalers might provide a double benefit for people ...

Researchers in the United Kingdom compared the potential impact on carbon footprint and asthma symptom control of switching maintenance therapy to a dry powder inhaler vs continuing with a metered ...

Shifting from a metered-dose inhaler to a dry-powder inhaler for chronic obstructive pulmonary disease (COPD) and asthma in one healthcare system formulary led to increased healthcare utilization, a ...

Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...

Switching from a metered-dose to a dry-powder inhaler after a formulary change increased emergency department visits and hospitalizations in people with COPD or asthma. The absolute changes in risk ...